Abstract:

Premature ovarian insufficiency (POI), characterized by the premature decline of ovarian function in women of reproductive age, significantly impairs quality of life and fertility. Its incidence has been rising globally. While conventional hormone replacement therapy (HRT) alleviated symptoms, its efficacy in restoring ovarian function or achieving pregnancy remains limited. With the emergence of regenerative medicine, platelet rich plasma (PRP) has garnered attention as a novel biologic therapeutic strategy. PRP, enriched with diverse growth factors, demonstrates potential to activate angiogenesis, cell proliferation, anti-apoptosis, and cell repair, thereby offering a promising avenue for ovarian regeneration. Preliminary clinical studies, though predominantly exploratory, suggest that PRP may improve the ovarian microenvironment, reactivate folliculogenesis, and enhance pregnancy rates. However, current evidence is constrained by small sample sizes and a lack of large-scale randomized controlled trials. The safety profile of PRP remains incompletely defined. While no serious adverse effects have been reported in POI applications, risks (e.g. infection, hypersensitivity) observed in other medical fields warrant caution. This review synthesizes the potential mechanisms of PRP in ovarian functional recovery, summarizes current clinical progress, and identifies key research gaps, aiming to provide a theoretical basis and research directions for clinical treatment.

Key words: Platelet-rich plasma, Regeneration, Therapy, Premature ovarian insufficiency, Biological therapy